PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics Limited is making progress in its clinical trials for a ground-breaking drug, VP-001, aimed at treating Retinitis Pigmentosa type 11, a childhood blinding eye disease. Notable safety and efficacy data will be presented by Associate Professor Fred Chen, demonstrating no serious adverse events and potential improvement in one patient’s retinal sensitivity. The company is refining patient selection criteria to focus on those at an earlier disease stage and will host an investor presentation to discuss these developments.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
